The recent $114m Series B round raised by Semma Therapeutics Inc. reflects two positive trends about the venture capital environment for biopharmaceuticals companies – both the number of companies and the amount of money raised by new and early-stage firms are rising.
Finance Watch: Semma Raises $114m As VC Funding Keeps Up Brisk Pace
Semma closed a $114m Series B round to fund development of insulin-producing cells. Also, Tesaro and Catalyst are among recent public company financings, while Otonomy shifted gears, laying off sales staff.
